Research Article

You have full text access to this OnlineOpen article

Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes

  1. Mona G. Sarkiss MD, PhD1,
  2. S. Wamique Yusuf MBBS, MRCPI2,
  3. Carla L. Warneke MD3,
  4. Gregory Botz MD1,
  5. Nasser Lakkis MD4,
  6. Cheryl Hirch-Ginsburg MD5,
  7. J. Chris Champion MD2,
  8. Joseph Swafford MD2,
  9. Andrew D. S. Shaw MD6,
  10. Daniel J. Lenihan MD2,
  11. Jean-Bernard Durand MD2,†,‡,*

Article first published online: 13 DEC 2006

DOI: 10.1002/cncr.22434

Issue

Cancer

Cancer

Volume 109, Issue 3, pages 621–627, 1 February 2007

Additional Information

How to Cite

Sarkiss, M. G., Yusuf, S. W., Warneke, C. L., Botz, G., Lakkis, N., Hirch-Ginsburg, C., Champion, J. C., Swafford, J., Shaw, A. D. S., Lenihan, D. J. and Durand, J.-B. (2007), Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer, 109: 621–627. doi: 10.1002/cncr.22434

Author Information

  1. 1

    Departments of Anesthesiology and Critical Care, University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Cardiology, University of Texas M. D. Anderson Cancer Center, Houston, Texas

  3. 3

    Division of Quantitative Sciences, University of Texas M. D. Anderson Cancer Center, Houston, Texas

  4. 4

    Department of Cardiology, Baylor College of Medicine, Ben Taub General Hospital, Houston, Texas

  5. 5

    Laboratory Medicine, University of Texas M. D. Anderson Cancer Center, Houston, Texas

  6. 6

    Department of Anesthesiology, Duke University, Raleigh, North Carolina

  1. †

    Dr. Jean-Bernard Durand is on the speaker's bureaus for Scios, GlaxoSmithKline, and Novartis.

  2. ‡

    Fax: (713) 745-1942

*Department of Cardiology, Unit 449, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030

Publication History

  1. Issue published online: 19 JAN 2007
  2. Article first published online: 13 DEC 2006
  3. Manuscript Accepted: 11 NOV 2006
  4. Manuscript Revised: 9 OCT 2006
  5. Manuscript Received: 17 JUL 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (162K)

REFERENCES

  • 1
    Hull MC,Morris CG,Pepine CJ,Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003; 290: 2831–2837.
  • 2
    Harris EE,Correa C,Hwang WT, et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol. 2006; 24: 4100–4106.
  • 3
    Braunwald E,Antman EM,Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002; 40: 1366–1374.
  • 4
    McClure MW, Berkowitz SD,Sparapani R, et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation. 1999; 99: 2892–2900.
  • 5
    Lip GY,Chin BS,Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 2002; 3: 27–34.
  • 6
    Luzzatto G,Schafer AI. The prethrombotic state in cancer. Semin Oncol. 1990; 17: 147–159.
  • 7
    Bobbio-Pallavicini E,Gugliotta L,Centurioni R, et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica. 1997; 82: 429–435.
  • 8
    Alarcon-Segovia D,Sanchez-Guerrero J. Correction of thrombocytopenia with small dose aspirin in the primary antiphospholipid syndrome. J Rheumatol. 1989; 16: 1359–1361.
  • 9
    Fayyad AM,Brummitt DR,Barker HF,Spooner SF. May-hegglin anomaly: the role of aspirin in the treatment of this rare platelet disorder in pregnancy. BJOG. 2002; 109: 223–224.
  • 10
    Nash GF,Turner LF,Scully MF,Kakkar AK. Platelets and cancer. Lancet Oncol. 2002; 3: 425–430.
  • 11
    Blann AD,Gurney D,Wadley M,Bareford D,Stonelake P,Lip GY. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul Fibrinolysis. 2001; 12: 43–50.
  • 12
    Caine GJ,Nadar SK,Lip GY,Stonelake PS,Blann AD. Platelet adhesion in breast cancer: development and application of a novel assay. Blood Coagul Fibrinolysis. 2004; 15: 513–518.
  • 13
    Macchi I,Chamlian V,Sadoun A, et al. Comparison of reticulated platelet count and mean platelet volume determination in the evaluation of bone marrow recovery after aplastic chemotherapy. Eur J Haematol. 2002; 69: 152–157.
    Direct Link:
  • 14
    Jachmann-Jahn U,Cornely OA,Laufs U, et al. Acute anterior myocardial infarction as first manifestation of acute myeloid leukemia. Ann Hematol. 2001; 80: 677–681.
  • 15
    Wu AH,Parsons L,Every NR,Bates ER. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol. 2002; 40: 1389–1394.
View Full Article (HTML) Get PDF (162K)